Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

[Spontaneous dissection of the upper mesenteric artery: a rare cause of acute abdominal pain].

Hoek J, Helleman J, Jansen J.

Ned Tijdschr Geneeskd. 2016;160:A9767. Dutch.

PMID:
27122072
2.

APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.

Leonard B, Starrett GJ, Maurer MJ, Oberg AL, Van Bockstal M, Van Dorpe J, De Wever O, Helleman J, Sieuwerts AM, Berns EM, Martens JW, Anderson BD, Brown WL, Kalli KR, Kaufmann SH, Harris RS.

Clin Cancer Res. 2016 Mar 25. [Epub ahead of print]

PMID:
27016308
3.

miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.

van Jaarsveld MT, van Kuijk PF, Boersma AW, Helleman J, van IJcken WF, Mathijssen RH, Pothof J, Berns EM, Verweij J, Wiemer EA.

Mol Cancer. 2015 Nov 17;14:196. doi: 10.1186/s12943-015-0464-4.

4.

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van ─▓cken WF, Heine AA, Smid M, Koudijs MJ, Brenton JD, Berns EM, Helleman J.

PLoS One. 2014 Sep 17;9(9):e103988. doi: 10.1371/journal.pone.0103988. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0122284.

5.

Reinterventions following endovascular abdominal aortic aneurysm repair: the learning curve of time.

Klompenhouwer EG, Helleman JN, Geenen GP, Ho GH, Vos LD, Van Der Laan L.

J Cardiovasc Surg (Torino). 2013 Jun;54(3):367-72. Epub 2012 Nov 8.

PMID:
23138601
6.

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.

van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA.

Oncogene. 2013 Sep 5;32(36):4284-93. doi: 10.1038/onc.2012.433. Epub 2012 Oct 8.

PMID:
23045278
7.

Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.

Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters DJ, Bachvarov D, Plante M, Berns EM, Helleman J, Van Laere SJ, van Dam PA.

PLoS One. 2011;6(7):e22469. doi: 10.1371/journal.pone.0022469. Epub 2011 Jul 25.

8.

Incarcerated vesico-inguinal hernia: a case report.

Helleman JN, Willemsen P, Vanderveken M, Cortvriend J, Van Erps P.

Acta Chir Belg. 2009 Nov-Dec;109(6):815-7.

PMID:
20184079
9.

Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.

Helleman J, Smid M, Jansen MP, van der Burg ME, Berns EM.

Gynecol Oncol. 2010 May;117(2):170-6. doi: 10.1016/j.ygyno.2010.01.010. Epub 2010 Feb 4.

PMID:
20132968
10.

MicroRNAs in ovarian cancer biology and therapy resistance.

van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA.

Int J Biochem Cell Biol. 2010 Aug;42(8):1282-90. doi: 10.1016/j.biocel.2010.01.014. Epub 2010 Jan 18. Review.

PMID:
20083225
11.

Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).

Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA.

Br J Pharmacol. 2010 Feb;159(4):898-908. doi: 10.1111/j.1476-5381.2009.00569.x. Epub 2010 Jan 8.

12.

Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs.

Helleman J, Jansen MP, Burger C, van der Burg ME, Berns EM.

Int J Biochem Cell Biol. 2010 Jan;42(1):25-30. doi: 10.1016/j.biocel.2009.10.016. Epub 2009 Oct 23. Review.

PMID:
19854294
13.

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer.

Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY, van Dam PA.

Br J Cancer. 2009 Mar 24;100(6):971-8. doi: 10.1038/sj.bjc.6604921. Epub 2009 Feb 24.

14.

Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.

Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM.

Clin Cancer Res. 2008 Sep 1;14(17):5555-64. doi: 10.1158/1078-0432.CCR-08-0555.

15.

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Helleman J, Sleijfer S, Klijn JG, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2009 Jul;116(2):263-71. doi: 10.1007/s10549-008-0125-z. Epub 2008 Jul 16.

PMID:
18629630
16.

Mycotic aneurysm of the descending thoracic aorta. Review and case report.

Helleman JN, Hendriks JM, Deblier I, Tran VT, Bouhouch A, Carp L, Lauwers P, Van Schil P.

Acta Chir Belg. 2007 Sep-Oct;107(5):544-7.

PMID:
18074916
17.

Serum proteomic patterns for ovarian cancer monitoring.

Helleman J, van der Vlies D, Jansen MP, Luider TM, van der Burg ME, Stoter G, Berns EM.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95. Epub 2007 Nov 20.

PMID:
18028381
18.

Gene expression profiling of treatment resistance: hype or hope for therapeutic target identification.

Helleman J, Jansen MP, Berns EM.

Int J Gynecol Cancer. 2006;16 Suppl 2:538-42. Review. No abstract available.

PMID:
17010068
19.

Mismatch repair and treatment resistance in ovarian cancer.

Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM.

BMC Cancer. 2006 Jul 31;6:201.

20.

Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.

Helleman J, Burger H, Hamelers IH, Boersma AW, de Kroon AI, Stoter G, Nooter K.

Cancer Biol Ther. 2006 Aug;5(8):943-9. Epub 2006 Aug 2.

PMID:
16775422
Items per page

Supplemental Content

Loading ...
Write to the Help Desk